Table 2.
Clinical parameters of patients with joint symptoms and without joint symptoms (n = 104).
| With joint Symptoms n = 33 |
Without joint symptoms n = 71 |
P value of chi square tests | Univariate Analysisa | Multivariate Analysisa | ||||
|---|---|---|---|---|---|---|---|---|
| Odds ratio (95% CI) | P value | Odds ratio (95% CI) | P value | |||||
| Age (years) | <55 55–65 65≤ |
5 19 9 |
3 34 34 |
P < .05 | 0.43 (0.21–0.86) | <.05 | 0.47 (0.21–1.05) | NS |
| Age at menarche (years) | <12 12–15 15≤ |
2 30 1 |
3 57 11 |
NS | 0.37 (0.11–1.21) | NS | ||
| No. of childbirths | None 1-2 2≤ |
2 24 7 |
8 21 42 |
NS | 1.14 (0.54–2.41) | NS | ||
| BMI (kg/m2) | <25 25–30 30≤ |
18 13 2 |
44 21 6 |
NS | 1.13 (0.60–2.15) | NS | ||
| Therapy prior to AI administration | None Yes |
18 15 |
48 23 |
NS | Not analyzedb | |||
| Time from menopausec (years) | <5 5–10 10≤ |
8 11 14 |
8 21 42 |
NS P = .056 (<5 ver 10≤) |
0.59 (0.34–1.02) | .059 | ||
| Pre-AI administration %YAM (%) | <70 70–80 80≤ |
6 12 12 |
25 30 12 |
NS | 1.98 (1.09–3.61) | <.05 | 1.65 (0.84 – 3.21) |
NS |
| Pre-AI administration %AGE (%) | <80 80–100 100≤ |
4 11 15 |
10 31 27 |
NS | 1.28 (0.68–2.39) | NS | ||
| Change of E2 | Rebound Decreased |
0 33 |
8 63 |
P < .05 | 2.52 (1.01–6.26) | <.05 | 2.28 (0.70 – 7.40) |
NS |
| Change of T-chold | Elevated Non-elevated |
16 13 |
15 49 |
P < .05 | 0.30 (0.13–0.71) | <.01 | 0.52 (0.22 – 1.25) |
NS |
| Change of %AGEd | Not -decreased Decreased |
17 13 |
44 22 |
NS | 1.63 (0.70–3.77) | NS | ||
BMI: body mass index; AI: aromatase inhibitor; %YAM: % young adult mean value; %AGE: % age-matched mean value; E2: estradiol; T-chol: total cholesterol; NS: not significance. aMaltivariate logistic regression analysis (trend analysis). bBecause of the diversity of the treatment methods employed, statistical analyses were not performed. cTime from menopause until AI administration. dExcluded patients with medicine.